In 2020, some 70 percent of new clinical trials were sponsored by smaller pharma companies, up from 60 percent in 2016. Unprecedented levels of venture-capital investment and increasing availability and breadth of outsourced capacity and capabilities paved the way for smaller companies to pursue innovation.
To read the article, see “Building pharma pipelines using a socioeconomic lens,” April 8, 2022.